IFNB1 and relapsing-remitting multiple sclerosis: Since IFN‐β therapy is an established treatment option in relapsing remitting multiple sclerosis (Steinman et al, 2012) and inhibits EAE via different cellular and humoral mechanisms (Inoue & Shinohara, 2013), we postulated an immunomodulatory potential in the eye.